Cytarabine
CAS No. 147-94-4
Cytarabine( 1-β-D-Arabinofuranosylcytosine | NSC 63878 | NSC 287459 | U-19920A )
Catalog No. M12042 CAS No. 147-94-4
Cytarabine (AraC) is an antimetabolic agent and DNA synthesis inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
25MG | 27 | In Stock |
|
50MG | 35 | In Stock |
|
100MG | 48 | In Stock |
|
200MG | 60 | In Stock |
|
500MG | 84 | In Stock |
|
1G | 99 | In Stock |
|
Biological Information
-
Product NameCytarabine
-
NoteResearch use only, not for human use.
-
Brief DescriptionCytarabine (AraC) is an antimetabolic agent and DNA synthesis inhibitor.
-
DescriptionCytarabine (AraC) is an antimetabolic agent and DNA synthesis inhibitor.(In Vitro):Cytarabine is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM. Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion.(In Vivo):Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity. Cytarabine is highly effective against acute leukaemias, which causes the Cytarabine teristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man.
-
In Vitro——
-
In Vivo——
-
Synonyms1-β-D-Arabinofuranosylcytosine | NSC 63878 | NSC 287459 | U-19920A
-
PathwayCell Cycle/DNA Damage
-
TargetDNA/RNA Synthesis
-
RecptorDNA synthesis
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number147-94-4
-
Formula Weight243.22
-
Molecular FormulaC9H13N3O5
-
Purity>98% (HPLC)
-
SolubilityWater: 48 mg/mL (197.35 mM); DMSO: 1 mg/mL (4.11 mM)
-
SMILESC1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Prakasha Gowda AS, et al. Biochemistry. 2010 Jun 15;49(23):4833-40.
molnova catalog
related products
-
RU320521
RU.521 (RU320521) is a potent?dsDNA?inhibitor (IC50 : 700?nM) inhibition of the dsDNA pathway by RU.521 requires the presence of cGAS.
-
Actinomycin D
A chemotherapy agent that has the ability to inhibit transcription.
-
Nedaplatin
Nedaplatin is a derivative of cisplatin and DNA damage agent for tumor colony forming units with IC50 of 94 μM.